| Literature DB >> 23512013 |
Radhakrishnan Sridhar1, Seeram Ramakrishna2.
Abstract
Nanotechnology based Pharma has emerged significantly and has influenced the Pharma industry up to a considerable extent. Nanoparticles technology holds a good share of the nanotech Pharma and is significant in comparison with the other domains. Electrospraying technology answers the potential needs of nanoparticle production such as scalability, reproducibility, effective encapsulation etc. Many drugs have been electrosprayed with and without polymer carriers. Drug release characteristics are improved with the incorporation of biodegradable polymer carriers which sustain the release of encapsulated drug. Electrospraying is acknowledged as an important technique for the preparation of nanoparticles with respect to pharmaceutical applications. Herein we attempted to consolidate the reports pertaining to electrospraying and their corresponding therapeutic application area.Entities:
Keywords: drug delivery; electrospray; nanomedicine; nanoparticle; sustained release
Mesh:
Year: 2013 PMID: 23512013 PMCID: PMC3749275 DOI: 10.4161/biom.24281
Source DB: PubMed Journal: Biomatter ISSN: 2159-2527

Figure 1. Projected timelines for Nanopharma “from research to market”.

Figure 2. Existing Nanomedicine in clinical usage.
Table 1. Nanotechnology based drug delivery systems classification
| Delivery Method/Routes of administration | Therapeutics | Technology |
|---|---|---|
| Oral administration | Cancer therapy | Nanoparticulate encapsulation |
| Transdermal delivery | Vaccines | Dendrimer-based targeted therapeutics technology |
| Injectable delivery | Antibody | Liposomes nanotechnology |
| Topical delivery | DNA-based therapy | Nanotube technologies |
| Nasal/pulmonary delivery | | Nanoparticles coating technology |
| Implantable delivery | | Silica-chitosan nanocomposite |
| | | Nanosome technology |
| | | Nanosuspension technology |
| | | Nanocrystal technology |
| | | Nanoshell technology |
| Polymer therapeutics |
Table 2. Nanotechnology products approved for market/in clinical trials
| Nanocrystalline drug products | Technology of /Licensed to (Year of approval) | Indication |
|---|---|---|
| Rapamune (Sirolimus), oral | Elan/Wyeth (2000) | Immunosuppressant |
| Emend (Aprepitant), oral | Elan/Merck (2003) | Antiemetic |
| Tricor (Fenofibrate), oral | Elan/Abbott (2004) | Treatment of high cholesterol and high triglycerides |
| Invega Sustena | Elan/Johnson and Johnson (2009) | Treatment of schizophrenia |
| | | |
| Liposomal drug products | | |
| Ambisome (Amphotericin B), IV | Gilead (1990) | Severe fungal infections |
| Abelcet (Amphotericin B), IV | Cephalon (1995) | Severe fungal infections |
| Depacyt (Cytarabine), Epidural | Napp (2002) | Neoplastic meningitis and lymphomatous meningitis |
| DepoDur (Morphine sulfate), Spinal | Flynn Pharma Limited (2004) | Pain Management |
| | | |
| Polymeric micelles | | |
| NK-911 (Doxorubicin), IV | Nippon Kayaku Co (Phase II) | Cancer targeting |
| NK-6004 (Cisplatin), IV | Nanocarrier Co (Phase II) | Cancer targeting |
| SP-1049C (Doxorubicin), IV | Anti-multidrug resistance (Phase II) | Supratek Pharma Inc. |
Table 3. Comparison of Nanoparticle synthesis methods
| Type | Method | Mechanism | Merits | Demerits | Application | ||
|---|---|---|---|---|---|---|---|
| Gas (Vapor) phase fabrication-Pyrolysis | Precursor vaporization, nucleation, growth | Simple, low cost, continuous operation, high yield | More chances of polymer, drug or biomaterial degradation | Calcium phosphate microspheres and Au nanoparticles for drug delivery | |||
| Liquid Phase Fabrication- Sol-Gel or solvothermal synthesis | Precursor solution (involves catalyst), nucleation, growth | Simple, low cost, continuous operation, high yield | Needs removal of catalyst components, May involve excess solvent usage for scale ups | Highly explored technology for drug delivery and biomedical applications | |||
| | |||||||
| Lithography, Etching, Milling or Machining | Braking down of large piece of material | offers reliability and device complexity | Higher energy spent and more waste produced | Electronic device Industry | |||
| Electrospraying | Driven by difference in electric potential and surface viscosity | Increased drug encapsulation efficiency, simplicity, low cost, continuous operation, high yield. | Chances of shear or thermal stress in some biomaterial nanoparticle synthesis | Has good prospects in drug delivery and pharma based industry | |||

Figure 3. Illustration for electro spraying technique.
Table 4. Therapeutic area and conditions for the synthesis of electrosprayed drug loaded micro/nanoparticles
| No | Polymer carrier | Drug encapsulated | Particle size (nm) | Therapeutic area | Condition |
|---|---|---|---|---|---|
| 1 | Polycapolactone | Budesonide | 116.1 ± 19 | Asthma | 0.5 to 6% PCL, |
| PLGA | Celecoxib | 1 to 4 µm | Anti-inflammatory | Total concentration at 5% PLGA+ drug, | |
| - | Carbamazepine | 320 to 1000 | Anticonvulsant | Up to 3 wt % solution, Flow rate up to 1.2 ml/h, Applied voltage 20 kV | |
| Lactose | Bovine Serum albumin (BSA) | 700 | Formulations as dry powder inhalers | 2% BSA with respect to solvent ethanol/acetic acid (96/4), Flow rate up to 0.3 ml/h, Applied voltage 5 kV | |
| Stearic acid and Ethyl cellulose | Tamoxifen | 922 ± 52 nm | Lipid nanoparticles (for Breast cancer treatment) | Polymer carrier/drug ratio was 10/1. Flow rate up to 0.6 ml/h, Applied voltage 30 kV. | |
| Polyvinylpyrrolidone (PVP) and Tristearin (GTS) | Naproxen | 720 ± 700 nm | Self-assembled solid lipid nanoparticles. (anti-inflammatory) | PVP/GTS/Naproxen ratio was 20/5/1. Flow rate up to 1 ml/h, Applied voltage 6–12 kV. |

Figure 4. Antimicrobial efficacy and bactericidal efficiency as a measure of silver/silica nanoparticle sample concentration.

Figure 5. SEM image of the composite lactose plus BSA obtained by EHDA and SDS-PAGE of the BSA not processed and of 4 different samples of the composite lactose–BSA. Lanes 1, 2 and 4, lactose exposed to the jet for 1200s. Lane 3, lactose exposed to the jet for 3600s.

Figure 6. Monodisperse wax emulsions produced with a collection solution of 80 wt% ethanol, 20 wt% water, 0.005 wt% of Tergitol 15-S-9 and 20 mM SDS. The flow rate is 4 ml/h and the voltage is 2.8 kV. (A) Micrograph of the hexagonal lattices of emulsion droplets confirms size uniformity. (B) Droplet size distribution measured by dynamic light scattering. The diameter of the droplets is 1.02 ± 0.03 μm, and the polydispersity is 2.7 ± 0.1%.

Figure 7. Quantum dot encoded microspheres synthesized by electrospraying.

Figure 8. Schematic representation of a coaxial needle arrangement for controlled generation of either cell-bearing droplets or threads.

Figure 9. Comparison of publications of electrosprayed nanoparticles and electrospun nanofibers (based on Scifinder search).